Alternating anti-prion regimens reduce combination drug resistance but do not further extend survival in scrapie-infected mice

References

1. Ghaemmaghami S, May BCH, Renslo AR, Prusiner SB. Discovery of 2-aminothiazoles as potent antiprion compounds. J Virol 2010; 84:3408–3412 [View Article]
   [Google Scholar]
2. Giles K, Olson SH, Prusiner SB. Developing therapeutics for prp prion diseases. Cold Spring Harb Perspect Med 2017; 7: [View Article] [PubMed]
   [Google Scholar]
3. Lu D, Giles K, Li Z, Rao S, Dolghih E et al. Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice. J Pharmacol Exp Ther 2013; 347:325–338 [View Article]
   [Google Scholar]
4. Wagner J, Ryazanov S, Leonov A, Levin J, Shi S et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson’s disease. Acta Neuropathol 2013; 125:795–813 [View Article] [PubMed]
   [Google Scholar]
5. Giles K, Berry DB, Condello C, Dugger BN, Li Z et al. Optimization of aryl amides that extend survival in prion-infected mice. J Pharmacol Exp Ther 2016; 358:537–547 [View Article] [PubMed]
   [Google Scholar]
6. Giles K, Berry DB, Condello C, Hawley RC, Gallardo-Godoy A et al. Different 2-aminothiazole therapeutics produce distinct patterns of scrapie prion neuropathology in mouse brains. J Pharmacol Exp Ther 2015; 355:2–12 [View Article] [PubMed]
   [Google Scholar]
7. Kawasaki Y, Kawagoe K, Chen C, Teruya K, Sakasegawa Y et al. Orally administered amyloidophilic compound is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner. J Virol 2007; 81:12889–12898 [View Article]
   [Google Scholar]
8. Berry D, Giles K, Oehler A, Bhardwaj S, DeArmond SJ et al. Use of a 2-aminothiazole to treat chronic wasting disease in transgenic mice. J Infect Dis 2015; 212:S17–S25 [View Article]
   [Google Scholar]
9. Leidel F, Eiden M, Geissen M, Kretzschmar HA, Giese A et al. Diphenylpyrazole-derived compounds increase survival time of mice after prion infection. Antimicrob Agents Chemother 2011; 55:4774–4781 [View Article] [PubMed]
   [Google Scholar]
10. Gunther EC, Smith LM, Kostylev MA, Cox TO, Kaufman AC et al. Rescue of transgenic alzheimer’s pathophysiology by polymeric cellular prion protein antagonists. Cell Rep 2019; 26:145–158 [View Article] [PubMed]
    [Google Scholar]
11. Ghaemmaghami S, Ahn M, Lessard P, Giles K, Legname G et al. Continuous quinacrine treatment results in the formation of drug-resistant prions. PLoS Pathog 2009; 5:e1000673 [View Article]
    [Google Scholar]
12. Berry DB, Lu D, Geva M, Watts JC, Bhardwaj S et al. Drug resistance confounding prion therapeutics. Proc Natl Acad Sci U S A 2013; 110:E4160–9 [View Article]
    [Google Scholar]
13. Bian J, Kang HE, Telling GC. Quinacrine promotes replication and conformational mutation of chronic wasting disease prions. Proc Natl Acad Sci U S A 2014; 111:6028–6033 [View Article] [PubMed]
    [Google Scholar]
14. Burke CM, Mark KMK, Kun J, Beauchemin KS, Supattapone S. Emergence of prions selectively resistant to combination drug therapy. PLoS Pathog 2020; 16: [View Article] [PubMed]
    [Google Scholar]
15. Kurt TD, Sigurdson CJ. Cross-species transmission of CWD prions. Prion 2016; 10:83–91 [View Article] [PubMed]
    [Google Scholar]
16. Castilla J, Gonzalez-Romero D, Saá P, Morales R, De Castro J et al. Crossing the species barrier by PrP(Sc) replication in vitro generates unique infectious prions. Cell 2008; 134:757–768 [View Article] [PubMed]
    [Google Scholar]
17. Morales R, Abid K, Soto C. The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta 2007; 1772:681–691 [View Article] [PubMed]
    [Google Scholar]
18. Hill AF, Collinge J. Prion strains and species barriers. Contrib Microbiol 2004; 11:33–49 [View Article] [PubMed]
    [Google Scholar]
19. Pattison IH. The relative susceptibility of sheep, goats and mice to two types of the goat scrapie agent. Res Vet Sci 1966; 7:207–212 [View Article] [PubMed]
    [Google Scholar]
20. Pattison IH, Jones KM. Modification of a strain of mouse-adapted scrapie by passage through rats. Res Vet Sci 1968; 9:408–410 [View Article] [PubMed]
    [Google Scholar]
21. Bartz JC, Bessen RA, McKenzie D, Marsh RF, Aiken JM. Adaptation and selection of prion protein strain conformations following interspecies transmission of transmissible mink encephalopathy. J Virol 2000; 74:5542–5547 [View Article] [PubMed]
    [Google Scholar]
22. Bartz JC. Prion strain diversity. Cold Spring Harb Perspect Med 2016; 6:12 [View Article] [PubMed]
    [Google Scholar]
23. Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J et al. Isolation of phosphatidylethanolamine as a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A 2012; 109:8546–8551 [View Article] [PubMed]
    [Google Scholar]